CRVS Corvus Pharmaceuticals Inc.

+0.09  (+2%)
Previous Close 3.92
Open 3.97
Price To Book 1.17
Market Cap 117600869
Shares 29,326,900
Volume 56,915
Short Ratio
Av. Daily Volume 71,362

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data at SITC November 2018 noted 1/33 PRs on monotherapy and 1/35 on combo.
Solid tumors - cancer
Phase 1/1b poster at ASCO June 1, 2019, 8am CT and presentation June 2, 2019, 9:24 am.
Solid tumors
Phase 1/1b data due late 2019.
Peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL)

Latest News

  1. Edited Transcript of CRVS earnings conference call or presentation 9-May-19 8:30pm GMT
  2. Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
  3. Corvus: 1Q Earnings Snapshot
  4. Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
  5. Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019
  6. Introducing Corvus Pharmaceuticals (NASDAQ:CRVS), The Stock That Slid 65% In The Last Three Years
  7. Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  8. Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
  9. Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
  10. Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
  11. Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer
  12. Have Insiders Been Buying Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares This Year?
  13. Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
  14. Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist
  15. Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher
  16. Sarepta Stock More Than Doubles This Year So Far: Here's Why
  17. Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding — New Horizons, Emerging Trends, and Upcoming Developments
  18. Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference
  19. Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting
  20. Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018